ResearchMoz.us include new market research report "Recombinant Coagulation Factors 2013" to its huge collection of research reports.
The report evaluates reasons for failures of novel recombinant coagulation factors and provides detailed profiles of active recombinant coagulation factors in clinical development. Preclinical projects are valued on the basis of the underlying technologies. Emerging alternative therapeutic approaches are described and assessed.
View Full Report With TOC: lhttp://www.researchmoz.com/recombinant-coagulation-factors-2013-the-race-to-market-and-for-market-shares-a-technology-and-pipeline-assessment-and-corporate-benchmarking-analysis-report.html
The detailed target pipeline assessments put emphasis on the competitive situation regarding stage of development, inhibitor profile, half-life, administration frequency, clinical success and especially time to approval/market. The pipelines of the clinically active companies are described and their competitive position assessed in light of the key success factors. Sources of information are LMP’s proprietary database, scientific literature (abstracts, papers), corporate information (press releases, presentations, reports, SEC filings). All information is referenced.
Combined product sales of the three classes olf recombinant coagulation factors used in hemophilia were US$ 7.172 mln in 2012. The pipeline of new recombinant coagulation factors is maturing and the first molecules are under regulatory review by the FDA and the EMA and many have entered pivotal clinical studies. There are 46 different molecules and R&D approaches for novel recombinant coagulation factors for hemophilia A and B in the pipeline of which 24 are in clinical development of under regulatory review. Given this tight competition, time-to-market will be an important success. This report will explain the potential development and approval timelines of each of the advanced molecules.
Buy a copy of this report: http://www.researchmoz.com/sample/checkout.php?rep_id=170272&type=S